High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists

We evaluated the differential effect of platelet count in platelet-rich plasma (PRP) on the level of ex vivo inhibition of platelet aggregation provided by abciximab, eptifibatide, and tirofiban as part of a randomized, comparative trial of these agents on platelet function in patients with unstable...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and thrombolysis 2000-02, Vol.9 (2), p.149-155
Hauptverfasser:	KEREIAKES, D. J, BRODERICK, T. M, ABBOTTSMITH, C. A, ROTH, E. M, WHANG, D, MUELLER, M, LACOCK, P, ANDERSON, L. C, HOWARD, W, BLANCK, C, SCHNEIDER, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Angina, Unstable - blood Angina, Unstable - drug therapy Antibodies, Monoclonal - pharmacology Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Confounding Factors (Epidemiology) Female Humans Immunoglobulin Fab Fragments - pharmacology Male Medical sciences Peptides - pharmacology Pharmacology. Drug treatments Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - pharmacology Platelet Count Platelet Function Tests Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Tyrosine - analogs & derivatives Tyrosine - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We evaluated the differential effect of platelet count in platelet-rich plasma (PRP) on the level of ex vivo inhibition of platelet aggregation provided by abciximab, eptifibatide, and tirofiban as part of a randomized, comparative trial of these agents on platelet function in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Platelet count
ISSN:	0929-5305 1573-742X
DOI:	10.1023/A:1018718914065